Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Gregor Frizzell

Gregor Frizzell

Partner
London +44 20 7067 2055 gfrizzell@cov.com Download V-card

Gregor Frizzell is a partner in, and a vice-chair of, Covington’s Corporate Practice Group. He is resident in the firm's London office. Mr. Frizzell's practice focuses on cross-border mergers and acquisitions and he also regularly advises clients on complex and strategic collaborations. His experience includes venture capital transactions, securities and finance, joint ventures, and general corporate and commercial advice. He has particular experience in the life sciences, energy, and technology sectors.

  • Represented AstraZeneca in connection with the $350,000,000 divestment of its rights to various respiratory products outside the U.S.
  • Represented AstraZeneca in connection with its strategic oncology collaboration with Innate Pharma S.A., including with respect to its acquisition of a nine percent interest in Innate Pharma.
  • Represented AstraZeneca in connection with its strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to discover, develop, and commercialize potential new medicines.   
  • Represented one of the world’s leading tire manufacturers in connection with three acquisitions of U.K. based digital technology companies.   
  • Represented AstraZeneca in connection with its $538,000,0000 divestment of its international rights to Seroquel.   
  • Represented AstraZeneca in connection with its $330,000,000 $divestment of its rights to Rhinocort Aqua outside the U.S.
  • Represented AstraZeneca in connection with two separate divestments of its global anaesthetics portfolio to Aspen Pharma.
  • Represented leading energy company in connection with its acquisition of interests in renewable energy assets in the Middle East.
  • Represented a global consumer goods company on its acquisition of a UK-based technology company.
  • Represented leading global biotechnology company in its acquisition of UK-based drug discovery company.
  • Represented leading global biotechnology company on its acquisition of a European based company.
  • Represented an investor in relation to the acquisition of oil and gas blocks in Africa.
  • Represented Magticom, Georgia’s leading telecoms company, in connection with a $100,000,000 loan from The European Bank for Reconstruction and Development for the acquisition of a fixed-line broadband internet network.
  • Represented AstraZeneca in connection with its strategic transaction with Almirall S.A.
  • Represented global pharmaceutical company in connection with its entry into a drug discovery joint venture with a partner in Japan.
  • Represented Allergan plc in connection with its acquisitions of 2 UK based early-stage companies.
  • Represented leading global mining and industrial company with the structuring and creation of its joint ventures in Turkey, Brazil, and Morocco.
  • Represented global pharmaceutical company in connection with its entry into a drug discovery joint venture with a partner in Korea.
  • Represented a global medical device company on its acquisition of a smaller, German-based medical device company.
  • Represented AstraZeneca in connection with the out-license of its European rights to Moventig.
  • Represented AstraZeneca in connection with the acquisition of rights to Actavis' Branded Respiratory Portfolio.
  • Represented AstraZeneca in connection with its $450,000,000 acquisition of Takeda’s Respiratory Business.
  • Represented MedImmune Ventures in connection with its investments in ADC Therapeutics.
  • Represented Consort Medical in connection with its acquisition financing facility of £160,000,000 to be used in connection with the acquisition of Aesica Holdco.
  • Represented lead and other investors in numerous investments into UK tech companies, including in Blippar, Fon, Chargemaster, Yplan, ip.access, Zesty, and others.
  • Represented lead investors in funding rounds of Formula E Holdings Limited.   
  • Represented ICICI Bank Limited and Standard Chartered Bank, as joint lead arrangers, on an aggregate of U.S. $925m in project financing supporting two Reliance Group infrastructure companies.
  • Represented Cenkos Securities PLC in relation to Tanfield Group PLC’s £115m placing of ordinary shares on AIM.
  • Represented telecoms borrower in relation to a $25m junior working capital facility.
  • Represented Thomson Reuters on English law aspects of the sale of its Medical Education business to ABRY Partners.
  • Represented SR One Limited, a venture capital fund, the lead investor in the Series C funding round for Addex Pharmaceuticals SA, a Swiss biotech company.
  • Represented Vantage Point Venture Partners on its Series A investment in Solar Century Holdings Limited.
  • Represented Giorgio Armani S.p.A. in relation to a cross-border acquisition and joint venture and on related licensing and franchising arrangements.
  • Represented QUALCOMM Inc. on its acquisitions of two UK venture-backed 3G-related software companies.
  • Represented a UK-listed private equity fund of funds on its recent share redemption.
  • Represented an early stage English biotech company on its Series B venture funding round.
  • Represented the majority shareholders of a UK venture-backed software company on the trade sale of the company to a U.S.-listed buyer.
  • Represented the founder and director of a UK software company in connection with the Series A venture funding round of his company.
  • Represented a U.S.-listed vaccines company on the spin-out of one of its medical device businesses to a venture-backed UK new company.
  • Legal 500 UK, M&A Premium Deals (2015-2016)
  • Legal 500 UK, Venture Capital (2015-2016)
  • Super Lawyers - London Rising Stars, Mergers & Acquisitions (2013)